These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 5357313)
21. [L-Dopa in the treatment of Parkinson's disease. (Considerations on 51 cases)]. Mazza C; Buffatti PF; Bazzan A; Lion P Fracastoro; 1970; 63(5):768-73. PubMed ID: 5519378 [No Abstract] [Full Text] [Related]
22. [Preliminary impressions of the therapeutic effectiveness of L-dopa in Parkinson's disease]. Buscaino GA; Campanella G Sist Nerv; 1970; 22(2):82-91. PubMed ID: 5504561 [No Abstract] [Full Text] [Related]
23. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease. Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950 [No Abstract] [Full Text] [Related]
26. Parkinson's disease: L-dopa treatment and handwriting area. Knopp W; Paulson G; Allen JN; Smeltzer D; Brown FD; Kose W Curr Ther Res Clin Exp; 1970 Mar; 12(3):115-25. PubMed ID: 4985489 [No Abstract] [Full Text] [Related]
27. Preliminary observations on L-dopa in the treatment of Parkinson's disease. Jelsma F; Roth R; Ross P; Davis J J Ky Med Assoc; 1971 Apr; 69(4):265-9. PubMed ID: 5577419 [No Abstract] [Full Text] [Related]
28. L-dopa and the patient with Parkinson's disease. Fangman A; O'Malley WE Am J Nurs; 1969 Jul; 69(7):1455-7. PubMed ID: 5192672 [No Abstract] [Full Text] [Related]
29. [Results of psychometic tests in 23 patients with Parkinson's disease after 6 months treatment with L-dopa]. Barbizet J; Duizabo P; Pasquier M Rev Neurol (Paris); 1972 Aug; 127(2):311-3. PubMed ID: 4666638 [No Abstract] [Full Text] [Related]
30. The modifying influence of L-dopa on the physical therapy program in Parkinson's disease. Blonsky ER; Minnigh EC Prog Phys Ther; 1970; 1(1):55-74. PubMed ID: 5523796 [No Abstract] [Full Text] [Related]
31. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease. Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775 [No Abstract] [Full Text] [Related]
32. Mortality in patients with Parkinson's disease treated with dopa. Singer RB J Insur Med; 1992; 24(2):126-7. PubMed ID: 10148480 [No Abstract] [Full Text] [Related]
34. Treatment of parkinsonism with levo-dopa: results in 302 cases. Newkirk TA; Magee KR Mich Med; 1971 Sep; 70(22):805-11. PubMed ID: 5141211 [No Abstract] [Full Text] [Related]
35. [Polygraphic study of nocturnal sleep in Parkinsonian syndromes. Effects of treatment levo-dopa]. Muratorio A; Murri L; Cerone G Riv Neurobiol; 1970; 16(4):361-76. PubMed ID: 4350093 [No Abstract] [Full Text] [Related]
36. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy. Lipman IJ; Papadopoulos NM Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194 [No Abstract] [Full Text] [Related]
37. Quantitative measurements of L-dopa therapy in Parkinson's disease. Webster DD Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483 [No Abstract] [Full Text] [Related]
38. Cerebral catecholamine concentration after L-dopa therapy in Parkinson's disease. Greer M; Anton AH Trans Am Neurol Assoc; 1970; 95():247-8. PubMed ID: 4328099 [No Abstract] [Full Text] [Related]
39. [Administration of L-dopa in Parkinson's syndrome and vitamin B6 metabolism]. Kuzuya F; Wakita T; Kawahara H Nihon Rinsho; 1973 May; 31(5):1108-15. PubMed ID: 4738416 [No Abstract] [Full Text] [Related]
40. The effects of L-dopa therapy in Parkinson's disease. Thompson RA; White JC; Echols CL Ariz Med; 1970 Jul; 27(7):5-10. PubMed ID: 5432717 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]